Last update Sept. 1, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Olmesartan Medoxomil in other languages or writings:
Olmesartan Medoxomil belongs to these groups or families:
Main tradenames from several countries containing Olmesartan Medoxomil in its composition:
|Oral Bioavail.||4.5 - 28.6||%|
|VD||0.2 - 0.4||l/Kg|
|Tmax||1 - 3||hours|
|T½||10 - 15||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once a day.
At latest update, relevant published data on excretion into breast milk were not found.
Its high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.
Until more data on this medication is available, safer alternative drugs are preferred (Malachias 2016, Rowe 2013), especially in premature babies or during the neonatal period.